Arvinas (ARVN) Operating Expenses (2017 - 2026)
Arvinas (ARVN) posted quarterly Operating Expenses of $79.4 million for Q1 2026, down 32.37% year-over-year from $117.4 million in Q1 2025, and down 5.59% quarter-over-quarter from $84.1 million in Q4 2025.
Arvinas (ARVN) Operating Expenses (2017 - 2026) Analysis & Trends
Arvinas' Operating Expenses history runs 10 years deep, the most recent figure standing at $79.4 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 32.37% year-over-year to $79.4 million; the TTM figure through Mar 2026 stood at $343.1 million (down 34.33% YoY), while the FY2025 annual figure was $381.1 million, down 25.8% from the prior year.
- Operating Expenses for Q1 2026 stood at $79.4 million, down from $84.1 million in the prior quarter.
- The five-year high for Operating Expenses was $162.7 million in Q3 2024, with the low at $79.4 million in Q1 2026.
- The 5-year median for Operating Expenses is $108.6 million (2024), against an average of $108.8 million.
- The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 78.39% in 2022, then slumped 47.33% in 2025.
- Arvinas' Operating Expenses stood at $113.4 million in 2022, then climbed by 7.76% to $122.2 million in 2023, then retreated by 3.93% to $117.4 million in 2024, then slipped by 28.36% to $84.1 million in 2025, then retreated by 5.59% to $79.4 million in 2026.
- Business Quant data shows ARVN's Operating Expenses at $79.4 million in Q1 2026, $84.1 million in Q4 2025, and $85.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - | 85.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 85.60 Mn |
| Mar 31, 2026 | 79.40 Mn |
| Dec 31, 2025 | 84.10 Mn |
| Sep 30, 2025 | 85.70 Mn |
| Jun 30, 2025 | 93.90 Mn |
| Mar 31, 2025 | 117.40 Mn |
| Dec 31, 2024 | 117.40 Mn |
| Sep 30, 2024 | 162.70 Mn |
| Jun 30, 2024 | 125.00 Mn |
| Mar 31, 2024 | 108.60 Mn |
| Dec 31, 2023 | 122.20 Mn |
| Sep 30, 2023 | 108.50 Mn |
| Jun 30, 2023 | 129.10 Mn |
| Mar 31, 2023 | 120.20 Mn |
| Dec 31, 2022 | 113.40 Mn |
| Sep 30, 2022 | 97.50 Mn |
| Jun 30, 2022 | 99.60 Mn |
| Mar 31, 2022 | 84.20 Mn |
| Dec 31, 2021 | 80.70 Mn |
| Sep 30, 2021 | 56.60 Mn |